ABK 3376
Alternative Names: ABK-3376Latest Information Update: 18 Sep 2023
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 01 Mar 2023 ABK 3376 licensed to Shanghai Allist Pharmaceuticals in China, Hong Kong, Macau, and Taiwan
- 01 Mar 2023 Preclinical trials in Non-small cell lung cancer (Combination therapy) in China (unspecified route), prior to March 2023 (Abbisko Therapeutics pipeline, September 2023)
- 01 Mar 2023 Preclinical trials in Non-small cell lung cancer (Monotherapy) in China (unspecified route), prior to March 2023 (Abbisko Therapeutics pipeline, September 2023)